|

ACB Stock Price: Aurora Cannabis Inc. advances nearly 10% to 0.75 pre-market

  • ACB points to a strong opening following Monday’s losses.
  • Stocks expected to react positively after Fed’s easing.

Aurora Cannabis Inc. (ACB) is sharply higher ahead of the opening bell in Wall Street, moving in tandem with the generalized upbeat mood in the pre-markets on Tuesday. Indeed, futures of the S&P and the DowJones are gaining around 5% at the time of writing on Tuesday.

In fact, US stocks markets are seen adding to the broad-based positive trading session in the Old Continent and Asia, as market participants keep adjusting to the recently announced extra easing measures by the Federal Reserve (Monday).

In the meantime, ACB is expected to regain some poise after Monday’s sharp sell-off to the 0.63 region after failing to advance further north of the 0.81 mark, closer to Friday’s top at 0.84.

Further out, ACB remains submerged into the multi-session consolidative theme prevailing since earlier in the month amidst the unremitting bearish view surrounding the company and despite some encouraging news coming in from California, where dispensaries said sales have ramped up as of late amidst the coronavirus lockdown.

It is worth mentioning that the extreme “oversold” condition of ACB (as per the daily RSI) could spark some near-term rebound. However, this view should be taken with a pinch of salt and could well represent selling opportunities. Supporting the latter, the ADX indicator – which gauges the strength of a trend – is at around 40, signalling a strong (down) trend.

Aurora Cannabis Stock Price

At the moment (pre-market), the stock is gaining 9.87% at 0.75 and faces the next hurdle at 0.81 (high Mar.23) seconded by 0.84 (weekly high Mar.20) and then 1.06 (21-day SMA). On the downside, a breach of 0.60 (2020 low mar.19) would open the door to 0.34 (monthly low Aug.2016) and finally 0.32 (monthly low Jul.2016).

Author

Pablo Piovano

Born and bred in Argentina, Pablo has been carrying on with his passion for FX markets and trading since his first college years.

More from Pablo Piovano
Share:

Editor's Picks

EUR/USD tests 1.1800 barrier above 50-day EMA

EUR/USD gains ground after three days of losses, trading around 1.1790 during the Asian hours on Thursday. The 14-day Relative Strength Index momentum indicator at 47 (neutral) reflects easing momentum. The RSI below 50 keeps momentum balanced and could limit follow-through.

GBP/USD struggles near four-week low vs. USD, below 1.3500 amid BoE rate cut bets

The GBP/USD pair is seen consolidating its weekly losses registered over the past three days and oscillating in a narrow range near a four-week trough, touched during the Asians session on Thursday. Spot prices currently trade just below the 1.3500 psychological mark and seem vulnerable to slide further.

Gold consolidates below $5,000 amid geopolitical risk, hawkish FOMC Minutes

Gold extends its sideways consolidative price move through the Asian session on Thursday and remains below the $5,000 psychological mark as traders seem hesitant amid mixed cues. The US Dollar preserves its strong gains to over a one-week high in the wake of somewhat hawkish Minutes of the US Federal Reserve’s January monetary policy meeting. 

Injective token surges over 13% following the approval of the mainnet upgrade proposal

Injective price rallies over 13% on Thursday after the network confirmed the approval of its IIP-619 proposal. The green light for the mainnet upgrade has boosted traders’ sentiment, as the upgrade aims to scale Injective’s real-time Ethereum Virtual Machine architecture and enhance its capabilities to support next-generation payments. The technical outlook suggests further gains if INJ breaks above key resistance.

Mixed UK inflation data no gamechanger for the Bank of England

Food inflation plunged in January, but service sector price pressure is proving stickier. We continue to expect Bank of England rate cuts in March and June. The latest UK inflation read is a mixed bag for the Bank of England, but we doubt it drastically changes the odds of a March rate cut.

Injective token surges over 13% following the approval of the mainnet upgrade proposal

Injective price rallies over 13% on Thursday after the network confirmed the approval of its IIP-619 proposal. The green light for the mainnet upgrade has boosted traders’ sentiment, as the upgrade aims to scale Injective’s real-time Ethereum Virtual Machine architecture and enhance its capabilities to support next-generation payments.